LENZ
LENZ Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.47
−1.00%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.60
From 52W high−89.15%
Volume671234.00
Market cap$108.87M
P/E (TTM)—
P/S (TTM)8.8x
Div yield—
Key dataNov 4, 2026
Open
$3.60
From 52W high
−89.15%
Volume
671234.00
Market cap
$108.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
P/E (TTM)
—
RSI (14)
49.2
MomentumView details →
1D Return
−1.00%
YTD Return
−78.26%
SummaryUpdated Sep 1, 2026
LENZ Therapeutics, Inc. (NASDAQ:LENZ) is a clinical-stage biopharmaceutical company founded to develop innovative treatments for presbyopia, a common age-related vision condition. The company went public in March 2024 and is headquartered in Del Mar, California. LENZ is currently preparing for the potential commercial launch of its lead product candidate LNZ100, which has completed Phase III clinical trials and has a pending New Drug Application (NDA) with the FDA, with a target approval date of August 8, 2025.
Similar companies
Latest newsMore news →
LENZ Therapeutics announced a restructuring that includes a 75% headcount reduction and projects 2027 operating expenses of $70 million to $75 million, a reduction of more than 50%.7d agoLENZ Therapeutics reported third-quarter 2026 revenue of $3.384 million, including $2.6 million in product sales, and a net loss of $30.969 million, or $0.99 per diluted share.7d agoLENZ Therapeutics, Inc. reported that VIZZ product sales in the third quarter of 2026 increased 50% from the prior quarter.7d ago